Reported Earnings • May 27
First quarter 2026 earnings released: kr0.11 loss per share (vs kr0.27 loss in 1Q 2025) First quarter 2026 results: kr0.11 loss per share (improved from kr0.27 loss in 1Q 2025). Revenue: kr2.25m (down 14% from 1Q 2025). Net loss: kr2.37m (loss narrowed 41% from 1Q 2025). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Tillkännagivande • May 18
AcouSort AB (publ), Annual General Meeting, Jun 18, 2026 AcouSort AB (publ), Annual General Meeting, Jun 18, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 406), scheelevagen 14, in lund, lund Sweden Tillkännagivande • Jun 25
AcouSort AB (publ) Approves Election of Stefan Blomsterberg and Per Sundkvist as New Board Members AcouSort AB (publ) at its AGM held on June 25, 2025, approved election of Stefan Blomsterberg and Per Sundkvist as new board members. Tillkännagivande • May 23
AcouSort AB (publ), Annual General Meeting, Jun 25, 2025 AcouSort AB (publ), Annual General Meeting, Jun 25, 2025, at 09:00 W. Europe Standard Time. Location: at medicon village building 406, scheelevagen 14, lund Sweden Tillkännagivande • May 06
AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million. AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 6,229,762
Price\Range: SEK 4
Transaction Features: Rights Offering Reported Earnings • Aug 29
Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2023) Second quarter 2024 results: kr0.32 loss per share (further deteriorated from kr0.24 loss in 2Q 2023). Revenue: kr1.99m (down 41% from 2Q 2023). Net loss: kr4.71m (loss widened 48% from 2Q 2023). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. New Risk • May 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (kr9.7m revenue, or US$912k). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€15.0m market cap, or US$16.3m). Reported Earnings • May 23
First quarter 2024 earnings released: kr0.25 loss per share (vs kr0.23 loss in 1Q 2023) First quarter 2024 results: kr0.25 loss per share (further deteriorated from kr0.23 loss in 1Q 2023). Revenue: kr2.97m (down 23% from 1Q 2023). Net loss: kr3.73m (loss widened 23% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Tillkännagivande • May 03
AcouSort AB (publ) to Present Two Posters Highlighting the Value of Acoustofluidics Sample Preparation AcouSort AB (publ) will exhibit and present at CYTO 2024 - demonstrating the benefits of acoustic sample preparation for flow cytometry applications. CYTO 2024, the 37th annual Congress of the International Society for the Advancement of Cytometry is an international conference on the many facets of cytometry science and engineering. In line with the company's focus on novel opportunities within cytometry, AcouSort will participate in the conference to present its innovative solutions for sample preparation and the vital role they can play to improve flow cytometry outcomes. AcouSort has also been selected to present two posters highlighting the value of acoustofluidics sample preparation. The first poster is presented by Dr Vera A Tang of University of Ottawa. During the spring of 2024, AcouSort has collaborated with Dr Tang and her team on the development of a new method for isolation of cells from dissociation tissue using the AcouWash. The poster describes how the AcouWash system is used to purify dissociation tissue samples and efficiently remove debris and dead cells from the target cells, something that is very difficult to do with other techniques. Dr Tang's main conclusions are that sample preparation using the AcouWash system offers a low-cost, gentle, and effective way to ensure that downstream analysis is performed on high quality viable samples. The second poster presents AcouSort's in-house work on high throughput cell wash and show new data on efficient and gentle cell wash at flowrates up to 5 mL/minute combined with a 5x up-concentration. By using acoustic cell wash, contaminants can be efficiently removed from the cells in a one-step process while retaining more than 98% of the cells. Proliferation studies also show that the AcouWash technology is very gentle to the cells and that cell proliferation after acoustic processing is the same as for unprocessed samples. The results presented in the poster is a great example on how acoustic sorting can be rapid, efficient, and gentle to the cells, combining several sample preparation steps into one. New Risk • Apr 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr33m free cash flow). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (kr11m revenue, or US$991k). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.7m market cap, or US$18.1m). Reported Earnings • Apr 02
Full year 2023 earnings released: kr1.29 loss per share (vs kr1.04 loss in FY 2022) Full year 2023 results: kr1.29 loss per share (further deteriorated from kr1.04 loss in FY 2022). Revenue: kr10.6m (up 23% from FY 2022). Net loss: kr17.1m (loss widened 24% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. New Risk • Dec 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.2m). Market cap is less than US$100m (€20.3m market cap, or US$22.0m). Tillkännagivande • Dec 02
AcouSort AB (publ) has completed a Composite Units Offering. AcouSort AB (publ) has completed a Composite Units Offering.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 515,526
Price\Range: SEK 45
Transaction Features: Rights Offering Reported Earnings • Nov 08
Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.32 loss in 3Q 2022) Third quarter 2023 results: kr0.33 loss per share (further deteriorated from kr0.32 loss in 3Q 2022). Revenue: kr2.16m (up 63% from 3Q 2022). Net loss: kr4.30m (loss widened 2.0% from 3Q 2022). Tillkännagivande • Nov 07
AcouSort AB (publ) to Report Q4, 2023 Results on Feb 28, 2024 AcouSort AB (publ) announced that they will report Q4, 2023 results on Feb 28, 2024 Tillkännagivande • Jun 17
AcouSort AB (publ) Recruits Henrik Johansson to the Position as Director of Research and Technology AcouSort AB (publ) has recruited Henrik Johansson to the position as Director of Research and Technology. Henrik has significant experience from startup environment within the biotech space as well as from R&D management roles at Agilent and PerkinElmer. Going forward, he will play a key role in the further development of the company's technology portfolio. As Director of Research and Technology, Henrik will be responsible for the company's Research projects. Primary focus will be on managing research activities aimed at further developing and applying the company's core technology to address unmet needs identified in clinical research and practice. Henrik will also be responsible for identifying new technology frontiers that enables development of products. Henrik has extensive knowledge of developing novel products based on proprietary technology and experience of leading product development projects from idea stage to product launch. Reported Earnings • Jun 01
First quarter 2023 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2022) First quarter 2023 results: kr0.23 loss per share (further deteriorated from kr0.20 loss in 1Q 2022). Revenue: kr3.85m (up 43% from 1Q 2022). Net loss: kr3.04m (loss widened 16% from 1Q 2022). Tillkännagivande • May 23
AcouSort AB (publ) Launches Next Generation AcouTrap at CYTO 2023 AcouSort launches next generation AcouTrap at CYTO 2023. CYTO is organized by the International Society for the Advancement of Cytometry and attended by leading researchers and instrumentation providers within flow cytometry. This year, AcouSort will use the conference to launch the new and much improved AcouTrap system. The conference is held in Montréal, Canada, May 20-24. The new AcouTrap 3 system comes with improved design and an updated and intuitive software graphical user interface (GUI), which simplifies user workflows. The new design and new software are based on customer feedback from AcouSort's last generation of AcouTrap. Along with the upgrades to the AcouTrap system, AcouSort also presents two new trapping units with improved performance. The smaller unit has a capacity of up to 100,000 cells and is d esigned for minute samples and rare cells, while the enhanced unit has higher throughput and can handle up to 0.5 million cells. Both units allow for gentle, automated handling with minimal cell loss . Reported Earnings • Feb 23
Full year 2022 earnings released: kr0.98 loss per share (vs kr0.92 loss in FY 2021) Full year 2022 results: kr0.98 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr8.59m (up 44% from FY 2021). Net loss: kr12.9m (loss widened 5.8% from FY 2021). Reported Earnings • Nov 24
Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.30 loss in 3Q 2021) Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.30 loss in 3Q 2021). Revenue: kr1.33m (up 79% from 3Q 2021). Net loss: kr4.22m (loss widened 22% from 3Q 2021). Reported Earnings • Aug 25
Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021) Second quarter 2022 results: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021). Revenue: kr1.81m (up 51% from 2Q 2021). Net loss: kr4.03m (loss widened 16% from 2Q 2021). Tillkännagivande • Aug 14
The European Innovation Council Awards the Acousort Project Acousome SEK 26 Million to Develop Technology for Exosome-Based Diagnostics The European Innovation Council awarded the AcouSort project AcouSome SEK 26 million to develop technology for exosome-based diagnostics. Exosomes are nanoparticles that enable human cells to communicate vital information with each other. They have potential to open a completely new field within diagnostics, as they can give `status reports' on organs such as the brain and heart, as well as give vital information on tumor diseases, infectious diseases, pregnancy and stem cells conditions. EIC has announced that they grant AcouSort and its project partners SEK 26 million to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort's partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU. In 2013, James E. Rothman, Randy W. Schekman and Thomas C. Südhof were awarded the Nobel Prize in Physiology - Medicine for their discoveries of exosomes. Since then, significant research has been done in this field, but so far, very few practical applications have been developed. The AcouSome project aims to develop a technology which separates exosomes from blood to enable a robust and reliable exosome-based diagnostics. If successful, the outcome of the project could open up a completely new and very promising field within diagnostics. Currently, there are no adequately efficient methods to automatically isolate exosomes from whole blood. The ambition of the AcouSome project is to develop a component which enables a one-step, fully automated process. Since blood potentially is a highly infectious substance, the aim is to design an affordable disposable solution to minimize the contamination risk implied in all re-usable instruments. One part of the project is therefore to devise a production platform which can ramp up product volumes to achieve a low unit cost. The proposal has been through a tough two-step evaluation process before being awarded. The final step involved pitching the proposal in front of a panel of six independent specialists. Tillkännagivande • Aug 10
AcouSort AB Announces Executive Appointments AcouSort AB is rapidly moving towards full commercialization of its solutions for point-of-care diagnostics. In parallel, the company sees a rapidly increasing interest for its technology within precision medicine. With the recruitment of Kelley Intehar as General Manager and Sales Director North America, AcouSort establishes an immediate presence in the US - the world's largest healthcare market. With the recruitment of Agnes Michanek as Commercial Director, AcouSort also enhances the company's corporate commercial function. Kelley Intehar comes from a position as Commercial Director/North American Sales Specialist at Bio-Techne Corporation. Kelley Intehar has a distinct commercial profile and a unique experience, network, and know-how. At Bio-Techne, Kelley Intehar established an entirely new business area, and she has in-depth knowledge of precision medicine. Agnes Michanek returns to AcouSort to take up the position as Commercial Director. Agnes Michanek has excellent external communication skills and will drive AcouSort's business development as the company intensifies its commercial efforts with the ambition to accelerate sales of its solutions for point-of-care diagnostics. Agnes was deeply involved in the development of AcouSort's current strategy, which she now will help turn into actions. Tillkännagivande • Aug 05
AcouSort AB (publ) and Werfen's Joint Patent Application Has Received National Approval in US AcouSort AB (publ) and its partner Werfen 's U.S. patent application received national approval in the United States on August 3, 2022. According to PCT regulations, the original international application was published in the database after April 7, 2018. The patent application concerns an acoustofluidics technology that separates blood plasma from whole blood and enables analysis of the plasma using either optical or electrical methods. The technology to which the patent application relates has been developed in collaboration between AcouSort and Werfen. The collaboration has resulted in Werfen using AcouSort's acoustics technology in the next generation of one of their clinical diagnostic instruments. Tillkännagivande • Jun 10
AcouSort AB (publ) Announces Scientific Progress with AcouWash Enables New Method for Cancer Treatment Monitoring AcouSort's first AcouWash customer, the prestigious US National Institute of Health (NIH), has published a scientific paper demonstrating the use of the system in a cancer treatment monitoring method. The study is part of a larger project where NIH aims to develop a clinical process using the AcouWash technology. As previously reported, NIH purchased the first AcouWash prototype in 2017 and has since used the system for an important cell wash step in their development of a new method for cancer treatment monitoring. The NIH researchers have conducted a study comparing AcouWash-based cell wash to a conventional centrifugation-based protocol. The results have now been published in Scientific Reports, a journal from the Nature Portfolio, successfully validating the AcouWash for the intended application. According to the authors of the publication, the study shows that acoustophoresis cell washing can be used in the design of an automated benchtop, GMP-qualified cell radiolabeling device. This is an important step toward a future integration of AcouSort's cell washing technology specifically designed as an automated clinical benchtop system for cancer treatment applications. Reported Earnings • May 19
First quarter 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in 1Q 2021) First quarter 2022 results: kr0.20 loss per share (down from kr0.15 loss in 1Q 2021). Revenue: kr2.69m (down 4.1% from 1Q 2021). Net loss: kr2.61m (loss widened 55% from 1Q 2021). Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr0.92 loss per share (down from kr0.70 loss in FY 2020). Revenue: kr5.96m (up 21% from FY 2020). Net loss: kr12.2m (loss widened 53% from FY 2020). Revenue was in line with analyst estimates. Reported Earnings • Nov 25
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Third quarter 2021 results: kr0.31 loss per share (down from kr0.20 loss in 3Q 2020). Revenue: kr739.0k (up 262% from 3Q 2020). Net loss: kr3.45m (loss widened 56% from 3Q 2020). Revenue was in line with analyst estimates. Tillkännagivande • Sep 23
AcouSort will launch AcouWash 2 at international conference AcouSort will launch the new version of its cell washing and separation system AcouWash during µTAS, an international conference attended by many industry professionals and key opinion leaders within Life Science held in October. The new version of the system features improved performance and a more user-friendly design. AcouWash is a benchtop research instrument that uses acoustic separation to wash or separate cells in for example a blood sample. Common applications include separation of specific, sensitive white blood cells and generation of very pure plasma from whole blood samples. The new version features higher throughput with improved temperature- and flow control. µTAS is an international conference on Miniaturized Systems for Chemistry and Life Sciences, where AcouSort this year will be a virtual exhibitor. Reported Earnings • Aug 26
Second quarter 2021 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.20m (down 17% from 2Q 2020). Net loss: kr3.48m (loss widened 160% from 2Q 2020). Tillkännagivande • Jun 17
AcouSort AB (publ) Announces Development Process of AcouPlasma Optical Reaches Important Milestone AcouSort AB (publ) announced that the development process of AcouPlasma Optical has now reached an important milestone. The project has reached design freeze, meaning that the final product design is finished. AcouPlasma Optical is the company’s first OEM product, aiming to be used as a third-party component that integrates sample preparation into analytical and diagnostic systems. After over a year of product development, the product design has been finalized and the project has reached an important milestone. The next steps are design verification, proving that the product meets its requirements, and manufacturing process validation. The final product will be launched during the fall 2021, but beta evaluation kits are already available to customers. In 2020, the company developed a quality management system to become an ISO13485-certified supplier of OEM components to the life science industry. AcouPlasma Optical is the first product being developed within that quality system. The production line for semi-automated production is already in place and the company will release additional commercial material during 2021 highlighting the commercial offering of the AcouPlasma Optical OEM module. Reported Earnings • May 28
First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.10 loss in 1Q 2020) The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr2.80m (up 34% from 1Q 2020). Net loss: kr1.69m (loss widened 65% from 1Q 2020). Tillkännagivande • Mar 15
Acousort Strengthens Commercial Offering with the Release of New Acouwash Application Notes AcouSort releases new marketing material showing the superiority of the company's technology compared to competitive techniques. With two new application notes on isolation of different blood components, the company further strengthens its commercial offering to customers in the Life Science industry and academia.
The new application notes show how AcouSort's technology can improve advanced sample preparations by workflow automation for isolation of platelets and mononuclear cells (MNC) from whole blood. With AcouWash processing, a higher sample quality is achieved compared to conventional techniques in a far less labor intense way. Isolation of platelets is of significant interest to enable studies of platelets as potential biomarker source for detection of diseases such as cancer and coagulation disorders, as well as for the development of platelet-based diagnostics. With the acoustic technology built into the AcouWash, isolation is simple, label-free, highly efficient and very gentle to the sensitive blood platelets. Separation of mononuclear cells (MNCs) from whole blood is a key process step prior to many different research, diagnostic and therapeutic procedures. The standard density centrifugation method is time- and labor consuming, requires large sample volumes and is ill-suited for integration. With the AcouWash technology, the process is automated and generates high quality results with superior cell viability. Reported Earnings • Feb 25
Full year 2020 earnings released: kr0.70 loss per share (vs kr0.96 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr6.82m (up 268% from FY 2019). Net loss: kr7.98m (loss narrowed 17% from FY 2019). Tillkännagivande • Feb 25
AcouSort AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021 AcouSort AB (publ) announced that they will report fiscal year 2020 results on Apr 14, 2021 
